A market research report by Custom Market Insights estimates the global veterinary regenerative medicine market to be valued at USD 401.21 million in 2024, reaching USD 452.97 million in 2025, and projected to grow to USD 1395.44 million by 2034 at a compound annual growth rate (CAGR) of 13.23% between 2025 and 2034. The market is driven by increasing demand for minimally invasive, sustainable treatments such as stem cell therapy and platelet-rich plasma (PRP) for conditions like osteoarthritis and ligament injuries in companion and livestock animals. Key players include VetStem Biopharma, Medrego, Ardent Animal Health, Zoetis, Boehringer Ingelheim Animal Health, Vetherapy, Celavet Inc., Gallant, Animal Cell Therapies Inc., ReGen Medicine, Epona Biotech, StemcellVet, Anicell Biotech, Companion Regenerative Therapies, EquiCord, Smith+Nephew (Veterinary Division), Owl Manor Veterinary, Exceed Equine, Regeneus Ltd., and Cell Therapy Sciences Ltd. The report highlights regional variations, with North America leading in adoption due to strong infrastructure and regulatory support, Europe advancing through clinical trials and research, and Asia-Pacific showing high growth potential due to rising pet ownership and government-backed initiatives. Regulatory developments by the FDA CVM and EMA are facilitating biologic therapies, while challenges such as high costs, insurance gaps, and lack of standardization remain significant barriers.

The global ENT devices market, valued at USD 16.80 billion in 2023, is projected to grow at a CAGR of 6.89% from 2024 to 2030, reaching USD 25.02 billion by 2030. Growth is driven by rising incidences of ear, nose, and throat disorders, including chronic conditions like cancer and allergic rhinitis, an aging population, and increasing hearing loss cases. Advancements in minimally invasive surgical technologies and the rise in plastic and reconstructive surgeries are key factors. North America is expected to dominate the market, particularly in the U.S., due to high prevalence of sinusitis, hearing loss, and head and neck cancers, along with strong healthcare infrastructure and public awareness. Key companies such as Cochlear Limited, Medtronic, Stryker, and Johnson & Johnson are active in the market, with several receiving FDA approvals for innovative devices like cochlear implants and automated ear-cleaning systems.

The global veterinary regenerative medicine market was valued at USD 401.21 million in 2024 and is projected to reach USD 452.97 million in 2025, with a forecast of USD 1395.44 million by 2034, growing at a CAGR of 13.23% from 2025 to 2034. Growth is driven by demand for minimally invasive, sustainable treatments such as stem cell therapy, platelet-rich plasma (PRP), gene therapy, and tissue engineering for orthopedic, wound healing, and dermatological conditions in companion and livestock animals. Advances in cell culture and autologous therapy kits enable in-house processing in veterinary clinics. Increasing focus on animal welfare, rising veterinary spending, and supportive regulatory frameworks in North America and Europe are accelerating adoption. The market is segmented by product type, application, animal type, and end-user. North America leads in adoption, Europe is research-intensive, and Asia-Pacific shows high growth potential. Key players include VetStem Biopharma, Medrego, Ardent Animal Health, Zoetis, Boehringer Ingelheim Animal Health, Vetherapy, Celavet Inc., Gallant, Animal Cell Therapies Inc., ReGen Medicine, Epona Biotech, StemcellVet, Anicell Biotech, Companion Regenerative Therapies, EquiCord, Smith+Nephew (Veterinary Division), Owl Manor Veterinary, Exceed Equine, Regeneus Ltd., and Cell Therapy Sciences Ltd. Strengths include reduced medication reliance, faster recovery, and improved quality of life. Weaknesses include high costs, inconsistent insurance coverage, and lack of standardization. Opportunities involve expansion into livestock and exotic species, integration with digital diagnostics, and development of off-the-shelf therapies. Threats include competition from traditional treatments, public skepticism, regulatory delays, and market consolidation.

A market research report by Allied Market Research projects that the global orthopedic implants market will grow from USD 47.19 billion in 2022 to USD 73.32 billion by 2032, registering a compound annual growth rate (CAGR) of 4.5% from 2023 to 2032. The report identifies key drivers including an aging population, technological advancements such as 3D printing and smart implants, rising sports injuries and trauma cases, minimally invasive surgeries, and increasing healthcare expenditure. Market segmentation by product type, biomaterial, and implant type shows that reconstructive joint replacements and metallic biomaterials dominate currently, while orthobiologics and spine implants are expected to grow at the fastest rates. Regionally, North America holds the largest market share in 2022, with Asia-Pacific projected to have the highest growth rate of 6.4% during the forecast period. Major companies in the market include Johnson & Johnson (DePuy Synthes), Stryker Corporation, Zimmer Biomet Holdings, Inc., NuVasive, Inc., Medtronic Plc, CONMED Corporation, Smith and Nephew Plc, DJO Finance LLC, Arthrex, Inc., and Globus Medical Inc.

Smith & Nephew reported strong Q2 revenue growth of 6.7% (7.8% including FX), driven by U.S. market expansion and emerging markets (excluding China) growth. The company highlighted margin expansion, free cash flow, and a $500 million share buyback, while addressing challenges in China, tariffs, and potential regulatory changes in the skin substitutes market.